Revolution Medicines, Inc. (RVMD)Healthcare | Biotechnology | Redwood City, United States | NasdaqGS
148.63 USD
-0.64
(-0.429%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 150.00 +1.37 (0.922%) ⇧ (April 17, 2026, 7:55 p.m. EDT) Short-term: ★★★★★ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:37 p.m. EDT
With the stock trading near $149, which is 15% below its 155.7 high but significantly above its 50 and 200-day moving averages, the macro setup is neutral-to-bearish for fundamentals, but the options chain is screaming 'buy the dip.' The heavy call concentration around strikes 130-150 suggests a high probability of a short-term squeeze or momentum play. Combined with the $2.2B capital raise that alleviates near-term cash-burn fears, the risk/reward for a 30-day momentum trade is heavily skewed toward upside, validating a 'strong buy' call position despite the negative earnings and the potential for insider selling to limit prices post-funding. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.057971 |
| AutoARIMA | 0.057972 |
| MSTL | 0.058821 |
| AutoTheta | 0.180516 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 9% |
| H-stat | 43.73 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 5.86 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 26.185 |
| Market Cap | 31,432,970,240 |
| Forward P/E | -24.58 |
| Beta | 1.01 |
| Website | https://www.revmed.com |
As of April 18, 2026, 11:37 p.m. EDT: Speculators are displaying a massive bullish imbalance. Call open interest forms a heavy 'yen' wall above the current price at strikes 130 and 150, while put activity is overwhelmingly in the far OTM region (straddles are effectively non-existent compared to calls). The near-term (April 17) expirations show significant ATM and ITM call volume with low underlying OI, suggesting leveraged speculation on a breakout. While some deep-OTM put interest exists, it is significantly lower in volume and open interest than the corresponding call gamma, indicating the market is buying gamma exposure for upside moves rather than hedging downside risk.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.065372 |
| Address1 | 700 Saginaw Drive |
| All Time High | 155.7 |
| All Time Low | 14.08 |
| Ask | 148.87 |
| Ask Size | 3 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 5,257,260 |
| Average Daily Volume3 Month | 2,907,777 |
| Average Volume | 2,907,777 |
| Average Volume10Days | 5,257,260 |
| Beta | 1.012 |
| Bid | 148.29 |
| Bid Size | 6 |
| Board Risk | 7 |
| Book Value | 8.281 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 148.63 |
| Current Ratio | 7.145 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 151.135 |
| Day Low | 145.52 |
| Debt To Equity | 26.185 |
| Display Name | Revolution Medicines |
| Earnings Call Timestamp End | 1,772,055,000 |
| Earnings Call Timestamp Start | 1,772,055,000 |
| Earnings Timestamp | 1,772,053,200 |
| Earnings Timestamp End | 1,778,097,600 |
| Earnings Timestamp Start | 1,778,097,600 |
| Ebitda | -1,174,619,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -23.715 |
| Enterprise Value | 27,855,980,544 |
| Eps Current Year | -7.72705 |
| Eps Forward | -6.04559 |
| Eps Trailing Twelve Months | -5.94 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 103.0878 |
| Fifty Day Average Change | 45.542206 |
| Fifty Day Average Change Percent | 0.44178075 |
| Fifty Two Week Change Percent | 306.5372 |
| Fifty Two Week High | 155.7 |
| Fifty Two Week High Change | -7.069992 |
| Fifty Two Week High Change Percent | -0.045407787 |
| Fifty Two Week Low | 34.0 |
| Fifty Two Week Low Change | 114.630005 |
| Fifty Two Week Low Change Percent | 3.3714707 |
| Fifty Two Week Range | 34.0 - 155.7 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,581,604,200,000 |
| Float Shares | 178,734,568 |
| Forward Eps | -6.04559 |
| Forward P E | -24.584864 |
| Free Cashflow | -523,279,008 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 883 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -987,331,968 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01831 |
| Held Percent Institutions | 0.96018 |
| Implied Shares Outstanding | 211,484,686 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. |
| Long Name | Revolution Medicines, Inc. |
| Market | us_market |
| Market Cap | 31,432,970,240 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_283775412 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -1,131,300,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 31,022,459,946 |
| Number Of Analyst Opinions | 19 |
| Open | 149.5001 |
| Operating Cashflow | -897,740,992 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 481 6801 |
| Post Market Change | 1.3699951 |
| Post Market Change Percent | 0.9217487 |
| Post Market Price | 150.0 |
| Post Market Time | 1,776,470,144 |
| Previous Close | 149.27 |
| Price Eps Current Year | -19.235025 |
| Price Hint | 2 |
| Price To Book | 17.948317 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.975 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.19048 |
| Region | US |
| Regular Market Change | -0.639999 |
| Regular Market Change Percent | -0.428753 |
| Regular Market Day High | 151.135 |
| Regular Market Day Low | 145.52 |
| Regular Market Day Range | 145.52 - 151.135 |
| Regular Market Open | 149.5001 |
| Regular Market Previous Close | 149.27 |
| Regular Market Price | 148.63 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 4,757,704 |
| Return On Assets | -0.30084 |
| Return On Equity | -0.58068 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 208,736,778 |
| Shares Percent Shares Out | 0.077800006 |
| Shares Short | 15,409,530 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 14,113,308 |
| Short Name | Revolution Medicines, Inc. |
| Short Percent Of Float | 0.082399994 |
| Short Ratio | 7.98 |
| Source Interval | 15 |
| State | CA |
| Symbol | RVMD |
| Target High Price | 200.0 |
| Target Low Price | 116.0 |
| Target Mean Price | 159.52632 |
| Target Median Price | 165.0 |
| Total Cash | 2,025,678,976 |
| Total Cash Per Share | 10.222 |
| Total Debt | 427,148,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.94 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 71.1878 |
| Two Hundred Day Average Change | 77.44221 |
| Two Hundred Day Average Change Percent | 1.0878578 |
| Type Disp | Equity |
| Volume | 4,757,704 |
| Website | https://www.revmed.com |
| Zip | 94,063 |